InterVivo Solutions and Mindset Pharma to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform

COPE Expected to Be World's First In Vivo Psychedelic Benchmark Data Set

InterVivo Solutions Inc. ("InterVivo" or "IVS" or the "Company"), a leading Canadian contract research organization providing preclinical in vivo research services that enable the pharmaceutical and nutraceutical industries to develop new products and therapies for neuropsychiatric and neurological diseases, is pleased to announce that it has entered a co-development agreement with Mindset Pharma Inc. (CSE: MSET) ("Mindset") to co-develop a new translational testing platform that will set the performance standards for breakthrough psychedelic medicines.

The psychedelics industry requires a standardized reference data set to identify and develop medicines with enhanced therapeutic benefit and improved safety and pharmacological profiles. InterVivo and Mindset intend to establish the first comprehensive psychedelics benchmark reference data set by evaluating a broad range of psychedelic drugs through a proprietary program of in vivo tests conducted at InterVivo's leading edge facility. The Cooperative Psychedelics Evaluation Platform ("COPE") will be an invaluable tool to guide the development of next-generation psychedelic compounds and improve patentability and value in new molecule drug assets. InterVivo and Mindset intend to make COPE available to InterVivo clients pursuing psychedelics drug development projects, with first data sets to be available by June 12th, 2021.

The project will be co-led by IVS's Chief Scientific Officer, Dr. Guy Higgins, and VP R&D, Dr. Inés de Lannoy, and will focus on establishing both pharmacological and pharmacokinetics data sets using sophisticated behavioural assays as well as state-of-the art in vivo sampling and analytical techniques. Mindset Pharma will co-sponsor the project and will incorporate the testing technology and data sets into their own lead optimization programs.

Dr. Guy Higgins, Ph.D., Chief Scientific Officer of the Company and a Scientific Advisory Board member of Mindset, commented: "To design better and safer drugs, we must carefully establish the limitations of the current psychedelics. The combination of our behavioural pharmacology, pharmacokinetic and early (non-GLP) safety expertise puts us in an excellent position to characterise these for the purpose of identifying improved molecules, both for standard-dosing and micro-dosing purpose. Our ultimate aim is to bring significant value to our sponsors who are active in this field."

James Lanthier, CEO of Mindset commented: "We are excited to partner with InterVivo in this innovative initiative. We believe that the COPE platform will be a unique asset and will create significant value for the emerging psychedelics drug development market. We expect that the data from COPE will help both Mindset and the broader psychedelics field to identify specific pharmacological improvements, strengthen IP rights, and achieve key development milestones faster and more cost-effectively."

For more information, please contact:
Sal Lemus
Director of Sales and Marketing
sall@intervivo.com

About InterVivo Solutions Inc.

InterVivo Solutions Inc. (IVS) is Canada's top neuroscience contract research organization, offering translational research services with a focus on next-generation neuroscience drug discovery. IVS offers in vivo proof of concept efficacy, drug metabolism, pharmacokinetics and early safety research studies for a global client base.
www.intervivo.com

About Mindset Pharma Inc.

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin along with its own proprietary compounds.
www.mindsetpharma.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/77916.

News Provided by Newsfile via QuoteMedia

The Conversation (0)
NorthStar Gaming Chairman and CEO Michael Moskowitz.

NorthStar Gaming Leverages Content to Create Engaged, Active Players, CEO Says

NorthStar Gaming (TSXV:BET,OTCQB:NSBBF) is leveraging its rich, compelling content to better engage its customers, which ultimately leads to higher revenue, said NorthStar Chairman and CEO Michael Moskowitz, following an earlier announcement that the company is rolling out enhancements to the Sports Insights content on its platform.

“From the time that we founded NorthStar Gaming, we took the view that providing compelling content would lead to higher engagement with our customers,” he said. "And we're finding just that. We're planning to launch Sports Insights 2.0 in the first half of 2024 with redesigned sports and homepages, live scoreboards and tickers, live odds, trending topics and a greater tie-in in terms of the player journey and promotional offers that we provide to them."

Moskowitz noted that leveraging content helps attract new customers, with several media organizations using the company’s content on their own sites. “Ultimately, these articles and this content will help to create awareness around the NorthStar Bets brand and platform, and ultimately drive traffic to our site, which will convert into revenue.”

Keep reading...Show less
hand touching phone

Game-changing Prospects for the iGaming Market

iGaming has grown considerably in recent years. Driven by innovations in web technology and a changing regulatory landscape, online casinos and sportsbooks are more popular than ever.

To understand how the landscape may change moving forward, investors should assess how the industry has evolved in recent years.

Keep reading...Show less
smartphone on podium

Top Trends Shaping the Canadian iGaming Market

From emerging technologies to evolving regulations, the trajectory of iGaming has changed substantially in recent years as the market has experienced significant growth.

In 2022, Ontario's provincial government introduced game-changing legislation that established a regulatory framework for iGaming. Due to this legislation, regulated iGaming successfully displaced the unregulated market, according to Attorney General Doug Downey, creating over 1.6 million active player accounts across more than 70 operator websites as of April 2023 — just over one year following the change.

Ontario's regulation has also laid the groundwork for widespread change in the iGaming space across Canada. As iGaming continues to evolve, it's important to have a deeper understanding of both new and existing trends that will shape the industry's future, as well as regulations.

Keep reading...Show less
NorthStar Gaming Holdings

NorthStar Gaming Holdings


Keep reading...Show less
NorthStar Gaming Announces New Partnership Agreement with BettorView

NorthStar Gaming Announces New Partnership Agreement with BettorView

Partnership strategically positions NorthStar to reach consumers in restaurants and bars across Ontario

NorthStar Gaming Inc. (TSXV: BET) is proud to announce it has entered a partnership agreement with BettorView that will enable NorthStar to engage with consumers in restaurants and bars across Ontario. The partnership provides NorthStar with the opportunity to further expand player acquisition across both sports wagering and online casino in a frictionless and convenient manner.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×